 NeuBase Therapeutics, Inc. Nasdaq: NBSE NeuBase or the Company, a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced that one of its core technologies, the Janus Base, has been recognized by The Scientist as a Top 10 Innovation of 2019. The bi-specific Janus nucleobases uniquely allow NeuBase to develop short oligonucleotide drugs targeting rare genetic diseases that can reach and bind double helixes in the human genome and RNA secondary structures. The technologys inventor and NeuBases chief scientific officer, Danith Ly, Ph.D., developed the Janus Base in his lab at Carnegie Mellon University. 